

High-definition colonoscopy versus Endocuff versus EndoRings versus Full-Spectrum Endoscopy  
for adenoma detection at colonoscopy: a multicenter randomized trial

Douglas K. Rex<sup>1</sup>, Alessandro Repici<sup>2</sup>, Seth A. Gross<sup>3</sup>, Cesare Hassan<sup>4</sup>, Prasanna L. Ponugoti<sup>1</sup>,  
Jonathan R. Garcia<sup>1</sup>, Heather M. Broadley<sup>1</sup>, Jack C. Thygesen<sup>1</sup>, Andrew W. Sullivan<sup>1</sup>, William  
W. Tippins<sup>1</sup>, Samuel A. Main<sup>1</sup>, George J. Eckert<sup>5</sup>, Krishna C. Vemulapalli<sup>6</sup>

1. Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, IN
2. Gastroenterology, Humanitas Research Hospital & Humanitas University via Manzoni, Milan, Italy
3. Gastroenterology, Tisch Hospital, NYU Langone Medical Center, New York City, New York
4. Gastroenterology, Nuovo Regina Margherita Hospital, Rome, Italy
5. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
6. Department of Public Health and Preventative Medicine, St. George's University, Grenada, W.I.

Douglas K. Rex M.D.  
Indiana University Hospital  
550 North University Boulevard  
Suite 4100  
Indianapolis, IN 46202  
Email: [drex@iu.edu](mailto:drex@iu.edu)  
Phone: 317-948-8741  
Fax: 317-944-5449

**Study contributions:** Rex: study design, data collection, manuscript drafting and revision; Repici, Gross, Hassan: study design and data collection, critical review and revision of the manuscript; Ponugoti, Garcia: data collection and management; Vemulapalli: study design and review of the manuscript, Broadley, Thygesen, Sullivan, Tippins: data collection and review of the manuscript; Eckert: statistical support and analysis

**Conflicts of Interests:** Rex: research support, Boston Scientific, Medivators, EndoChoice, EndoAid, Braintree Laboratories, Medtronic, Colony Solutions, PAION, US Endoscopy; consultant: Boston Scientific, Olympus Corporation; Repici; Gross: consultant Cook Medical, Boston Scientific, Olympus Corporation, Medivators

This work was supported by a gift to the Indiana University Foundation from Scott Schurz of Bloomington, Indiana in the name of Douglas K Rex

---

This is the author's manuscript of the article published in final edited form as:

Rex, D. K., Repici, A., Gross, S. A., Hassan, C., Ponugoti, P. L., Garcia, J. R., ... Vemulapalli, K. C. (2018). High-definition colonoscopy versus Endocuff versus EndoRings versus Full-Spectrum Endoscopy for adenoma detection at colonoscopy: a multicenter randomized trial. *Gastrointestinal Endoscopy*. <https://doi.org/10.1016/j.gie.2018.02.043>

## Abstract

Background: Devices used to improve polyp detection during colonoscopy have seldom been compared with each other.

Methods: We performed a 3-center prospective randomized trial comparing high-definition (HD) forward-viewing colonoscopy alone to HD with Endocuff to HD with EndoRings to the Full Spectrum Endoscopy (FUSE) system. Patients were age  $\geq 50$  years and had routine indications and intact colons. The study colonoscopists were all proven high-level detectors. The primary endpoint was adenomas per colonoscopy (APC)

Results: Among 1,188 patients who completed the study, APC with Endocuff (APC Mean  $\pm$  SD  $1.82 \pm 2.58$ ), EndoRings ( $1.55 \pm 2.42$ ), and standard HD colonoscopy ( $1.53 \pm 2.33$ ) were all higher than FUSE ( $1.30 \pm 1.96$ ), ( $p < 0.001$  for APC). Endocuff was higher than standard HD colonoscopy for APC ( $p = 0.014$ ). Mean cecal insertion times with FUSE ( $468 \pm 311$  seconds) and EndoRings ( $403 \pm 263$  seconds) were both longer than with Endocuff ( $354 \pm 216$  seconds) ( $p = 0.006$  and  $0.018$ , respectively).

## Conclusions

For high-level detectors at colonoscopy, forward-viewing HD instruments dominate the FUSE system, indicating that for these examiners image resolution trumps angle of view. Further, Endocuff is a dominant strategy over EndoRings and no mucosal exposure device on a forward-viewing HD colonoscope.

## Introduction

Colonoscopy prevents colon cancer through detection and removal of precancerous lesions<sup>1</sup>.

More-effective detection of adenomas is associated with better prevention of postcolonoscopy

cancer<sup>2,3</sup>. Critical elements of effective detection include optimal maneuvering of the colonoscope to expose mucosal behind folds, adequate distension, clean colon, and sufficient inspection time to visually process the exposed mucosa<sup>4</sup>. The use of high-definition colonoscopes adds to detection<sup>5</sup> and is now widely considered fundamental to detection and effective therapeutics.

Although optimal maneuvers and lesion recognition ability during colonoscopy examination are the core of effective detection and can be taught to colonoscopists<sup>6,7</sup>, adjunctive devices and techniques have also been widely investigated. These include tools to highlight flat and subtle precancerous lesions such as chromoendoscopy<sup>8,9</sup> and electronic chromoendoscopy<sup>10,11</sup>, as well as mucosal exposure devices such as Endocuff<sup>12</sup>, EndoRings<sup>13</sup>, and ultra-wide angle endoscopes such as Full Spectrum Endoscopy (FUSE)<sup>14</sup>.

Available data with mucosal exposure devices have often compared such devices with standard colonoscopy in 2-arm studies. The most robust data is available for Endocuff<sup>12,15-18</sup>, and indicates that Endocuff produces an average 7% gain in the adenoma detection rate (ADR)<sup>12</sup>. Data are more limited with EndoRings, and are largely from a single randomized tandem study showing that EndoRings reduced the miss rate for adenomas<sup>14</sup>. Data on the value of the FUSE system have been mixed, with FUSE resulting in less missing in an initial tandem study<sup>14</sup>, but no improvement in a subsequent randomized trial in patients with positive fecal immunochemical tests<sup>19</sup>. To the extent that mucosal exposure devices are effective, it remains uncertain which colonoscopists can improve detection with these devices. That is, do all endoscopists improve

detection by use of mucosal exposure devices, or are the benefits confined or result predominantly for colonoscopists with low baseline ADRs?

In this study, we sought to evaluate the utility of mucosal exposure devices in the hands of colonoscopists with known high ADRs when using standard equipment. In addition, we sought to directly compare 3 mucosal exposure devices with each other, namely Endocuff versus EndoRings versus FUSE.

## Methods

We conducted a prospective randomized controlled trial comparing high-definition (HD) forward-viewing white-light colonoscopy (referred to as the standard or control arm), versus HD forward-viewing white-light colonoscopy plus Endocuff, versus HD forward-viewing white-light colonoscopy with EndoRings versus the Full Spectrum Endoscopy (FUSE) system. Patients were randomized in a 1:1:1:1 ratio. The study was conducted at 3 academic endoscopy units in Indianapolis, Indiana; Milan, Italy; and New York, New York. The study was reviewed and approved by the Institutional Review Boards at Indiana University on January 14, 2015, and all subjects gave informed consent. The trial was registered at Clinicaltrials.gov (NCT02345889).

Participants were  $\geq 50$  years and undergoing colonoscopy for colorectal cancer screening, surveillance of polyps, or symptoms. Patients were excluded if there was any previous surgical resection of the colon, if there was a known colonic stricture or severe diverticular disease that might impede passage of the colonoscope with Endocuff or EndoRings, if there was a known

coagulopathy, for inability to provide informed consent, for any known polyp syndrome or inflammatory bowel disease, or Lynch syndrome, or if the indication was a known therapeutic procedure including polypectomy (Table 1). Patients were excluded after randomization if their bowel preparation was considered inadequate for polyp examination, if the patient was found to have a polyp syndrome (World Health Organization criteria were used to classify patients with serrated polyposis syndrome<sup>20</sup>) based on the findings of the colonoscopy, or if the patient was diagnosed with inflammatory bowel disease during the study colonoscopy. As part of this intent to treat analysis, patients remained in the analysis if Endocuff or EndoRings on a pediatric colonoscope could not pass the sigmoid colon.

## Interventions

The study was performed at 3 sites, 2 in the United States and 1 in Italy. The original plan was to conduct the study at 4 sites, but the fourth site never initiated the trial. At each site one endoscopist with a proven high ( $\geq 40\%$  in screening colonoscopy) baseline ADR (DR, AR, and SG) performed every withdrawal. All 3 sites had extensive experience with control arm equipment, FUSE, and Endocuff before initiation. Two sites were less familiar with EndoRings and the endoscopists performed enough procedures with EndoRings before study initiation to be very familiar with its use. Fellows were allowed to insert the colonoscope, but cecal insertion times were evaluated separately when fellows participated in insertion.

A computer-generated sequence was used to randomize the patients. Each site was provided with a series of opaque envelopes numbered sequentially with the concealed randomization. Enrollment and assignment of patients to study arms occurred at the individual sites. The randomization was revealed only after the patient provided informed consent.

At all 3 sites, Olympus HD colonoscopes were used for the control arm and the arms with Endocuff and EndoRings. These were 190 series or H180 series colonoscopes, and the colonoscopists had the discretion to select an adult or pediatric instrument. If an adult instrument could not pass an angulated sigmoid, the protocol required an attempt with a pediatric instrument in the same randomization arm. Thus, patients randomized to Endocuff were required to have an attempt using the pediatric colonoscope with the pediatric Endocuff device.

The resolution of the FUSE system was improved by the manufacturer while the study was in progress. All 3 sites had access and incorporated the most up to date FUSE colonoscopes as they became available. Both adult and pediatric FUSE colonoscopes were available at each site.

The Endocuff device used was the original device with 2 rows of fingers (Arc Medical Design, Leeds, England). The EndoRings device was manufactured in Israel by EndoAid Ltd (Caesarea, Israel). During the study, the device was modified from a 3 ring device to a 2 ring device, and the EndoRings used were changed as soon as the new device was available.

The FUSE system and colonoscopes were provided by Endochoice (Marietta, Ga). The EndoRings devices were provided by EndoAid. The Endocuff devices were provided by the U.S. Endocuff distributor (Medivators Inc, Minneapolis, Minn). No other industry support was provided for the trial. There was no industry involvement in the design of the trial or its conduct, and no industry had access to or reviewed the study data or the manuscript before publication.

Each of the study endoscopists was asked to force the inspection time during withdrawal to approximately 8 minutes, in order to remove inspection time as a variable that could affect the detection results. Inspection time was measured during withdrawal by an assistant using a stopwatch. The stopwatch was started as soon as the cecum was cleaned and cecal inspection initiated. It was stopped for all maneuvers, including polypectomy and biopsy, and during all washing and suctioning of the colon. For the FUSE device, the endoscopist tried to observe all 3 screens, but 2 individuals (usually the technician and the registered nurse in the room) were assigned to watch the 2 lateral images (one assistant assigned to each screen) to help ensure that any exposed polyp was recognized.

#### Outcomes

The primary outcome was the rate of conventional adenomas per colonoscopy (APC). Secondary outcomes included the adenoma detection rate (ADR; percent of patients with  $\geq 1$  conventional adenoma), sessile serrated polyps per colonoscopy (SSPC; number of sessile serrated polyps per colonoscopy), the sessile serrated detection rate (SPDR or number of

patients with  $\geq 1$  sessile serrated polyp), the colonoscopy insertion times, the failure rate of insertion, and the detection targets noted above for the right side of the colon (cecum, ascending, and hepatic flexure). No interim analysis was performed.

Conventional adenomas were uniformly dysplastic lesions that were characterized as tubular, tubilovillous or villous with dysplasia as low grade or high grade. Serrated class lesions included hyperplastic polyps, sessile serrated polyps, and traditional serrated adenomas.

Because of failure of initiating the study at 1 planned site, and slow randomization at another, randomization was continued beyond the initial planned number at 2 sites (see results).

Proximal colon refers to the cecum, ascending colon, and hepatic flexure.

#### Sample size and statistical analysis

Based on previous studies at Indiana University we estimated that the baseline APC in the standard colonoscopy group would be 1.7 with a coefficient of variation of 1.5. In order to demonstrate an increase in APC to 2.2 ( an absolute increase of 0.5 or a 29% increase), in any of the 3 increased mucosal exposure groups, a sample size of 287 patients per group, or total sample of 1,148 subjects was needed, assuming 80% power, and 2-sided 5% significance level.

Generalized estimating equation (GEE) methods were used to analyze the combined data across all 3 sites, using site as the cluster effect. Age and Boston Bowel Preparation Score (BBPS) assumed normal distributions, insertion and withdrawal times assumed log-normal

distributions, count data used a negative binomial model, and binary data used logistic regression. Similar analyses, without using GEE for clustering, were performed for analyses of each site separately. Pair-wise tests between all groups were performed when the overall group effect was significant. A 5% significance level was used for all tests, with no adjustment for multiple comparisons. Analyses were performed using SAS version 9.4 (SAS institute, Inc, Cary, NC).

To assess the effect of changing the FUSE and EndoRings technology during the study, APC was plotted against time for the EndoRings and FUSE groups, with a spline added to the plot to evaluate trends.

## Results

Data on patients screened, deemed ineligible, and refusal to participate were collected only in Indianapolis. The flow of patients through the study, including those excluded after randomization at all 3 sites, are described in Figure 1.

Exclusions after screening and before randomization were tracked at Indianapolis only.

Subjects who passed initial screening at Indianapolis but were excluded before randomization included 17 identified to have some degree of prior colon resection, 4 were referred for a previous incomplete colonoscopy (this reason for referral was not evident to screeners in the initial portion of the study), 9 had evidence of inflammatory bowel disease, 4 had serrated polyposis syndrome, 1 had familial adenomatous polyposis, 1 had a positive fecal blood test, and 6 were considered unable to give informed consent by the investigator for reasons including dementia, anxiety, and inadequate English language skill. Seventeen were excluded by the investigator based on evidence of severe sigmoid diverticular disease in prior

colonoscopy reports (considered to make passage of the colonoscope with Endocuff or EndoRings likely to fail) or recent diverticulitis.

There were 1262 patients randomized, of whom 74 were excluded after randomization (Figure 1). One patient was excluded from the control arm for failure to intubate the cecum (Figure 1). Three patients were excluded when they were recognized to have serrated polyposis syndrome during the study colonoscopy. There were 6 patients randomized to EndoRings and 4 to Endocuff in whom the instrument could not pass the sigmoid with either adult or pediatric versions who were included in the intent to treat analysis. There were 3 patients in the EndoRings arm and 1 in the Endocuff arm in whom the adult scope with device could not pass the sigmoid but the pediatric colonoscope and device were successfully passed to the cecum. In one patient the FUSE processor failed during the procedure and could not be promptly repaired. The procedure was completed using a standard Olympus colonoscope and the patient was included in the study.

There were 1,188 subjects who completed the study, of whom 299 were randomized to Endocuff, 295 (Figure 2) to EndoRings, 299 to FUSE, and 295 to the control arm colonoscopy. The mean age of all subjects who completed the study was 62.6 (8.3) years and there were 582 (49%) women. There were 784 subjects who completed the study at Indianapolis, 302 at Milan, and 102 at New York. Table 2 shows demographic features and procedure indications for the 4 colonoscopy groups. There were no significant differences in these factors between groups, either overall or at the individual study sites. More than 90% of patients had polyp surveillance or screening as their indication.

## Detection

Considering only patients with the indication screening and who were randomized to the control arm, the fraction of subjects with at least one conventional adenoma (the adenoma detection rate or ADR using standard forward-viewing high-definition instruments) was 39 of 64 subjects (61%) at Indianapolis, 19 of 44 (43%) at Milan, and 16 of 19 (84%) at New York, consistent with previous internal data at each site that the study endoscopists were high-level detectors.

Table 3 summarizes detection in each study arm for all sites combined and individual sites. The control colonoscopy arm, Endocuff, and EndoRings were all superior to FUSE for the primary endpoint ( $p < 0.001$ ). Overall, the highest APC was achieved with Endocuff at 1.82 (2.58). Endocuff was superior to control colonoscopy (0.014). The most marked differences in detection with Endocuff were in New York, where APC was 2.00 (2.34) with Endocuff and  $<1$  with the other 3 modalities ( $0.75 \pm 0.94$  for EndoRings,  $0.80 \pm 1.37$  for FUSE,  $0.92 \pm 1.15$  for control). There were no differences in Indianapolis ( $p=0.151$ ) or Milan ( $p=0.848$ ) between the modalities for the primary endpoint.

The adenoma detection rate (ADR) was also significantly higher with Endocuff, EndoRings, and control colonoscopy compared to FUSE ( $p \leq 0.006$ ). Further, Endocuff was superior to EndoRings ( $p < 0.001$ ) and control colonoscopy ( $p=0.003$ ). There were no significant differences between study arms in ADR within sites. Similar findings were observed for the polyp detection rate (PDR) as were seen with ADR.

Evaluation by location in the colon showed that APC was higher in the right side of the colon (cecum, ascending, and hepatic flexure) for Endocuff ( $p < 0.001$ ), EndoRings ( $p = 0.043$ ) and control ( $p = 0.003$ ) compared with FUSE (Supplementary Table 1). APC for Endocuff in the right side of the colon was higher than control colonoscopy ( $p = 0.034$ ). When analyzed by site, APC with Endocuff was higher in the right side of the colon in New York when compared with EndoRings ( $p = 0.005$ ) and control ( $p = 0.030$ ), but there were no differences in right-sided colon ADR between modalities in Indianapolis ( $p = 0.563$ ) or in Milan ( $p = 0.966$ ). Very similar differences between modalities were seen in right-sided colon ADR at New York specifically; however, these differences in right-sided colon ADR between modalities were again not seen in Indianapolis ( $p = 0.382$ ) or Milan ( $p = 0.805$ ).

The detection endpoints in a per protocol analysis are shown in Supplementary Table 2.

Compared with the ITT analysis shown in Table 3, the per protocol analysis does not include the 10 patients in whom the colonoscope could not be passed through the sigmoid with a device on the tip and the one patient in whom the FUSE system failed. Differences in results between the ITT and PP analyses were minor.

There were no differences between modalities in APC for conventional adenomas  $\geq 10$  mm either overall ( $p = 0.306$ ) or at any of the study sites. Supplementary Table 1 shows the actual numbers of histologically identified conventional adenomas and sessile serrated polyps according to lesion size and location in the colon (right side of colon including cecum, ascending flexure, and hepatic flexure vs distal to the hepatic flexure).

There were some statistically significant differences in detection of SSPs between modalities (Table 3), but the trends were not consistent and although statistically significant, were numerically minor.

Because the technology for FUSE and Endorings were changed during the study, APC was plotted against time for each technology, and no significant trends over time were observed for FUSE ( $p=0.46$ ) or EndoRings ( $p=0.83$ ).

#### Procedure Times

For the entire study, cecal insertion time was longer with FUSE compared to Endocuff ( $p=0.006$ ) and control colonoscopy ( $p=0.016$ ) (Table 4). Further, EndoRings insertion time was longer than Endocuff ( $p=0.020$ ). A gastroenterology fellow was involved in the insertion phase in 39% of colonoscopies at Indianapolis, 61% of colonoscopies in Milan, and none of the colonoscopies in New York. When only colonoscopies in which no fellow participated in insertion were considered, the cecal insertion time was still longer with FUSE than the other 3 arms ( $p \leq 0.017$ ) and EndoRings was longer than Endocuff ( $p=0.014$ ). When insertion times by site were evaluated, FUSE was longer than Endocuff ( $p \leq 0.02$ ) and standard ( $p \leq 0.03$ ) at all sites, FUSE was longer than EndoRings in Indianapolis, and EndoRings was longer than Endocuff ( $p=0.023$ ) and standard ( $p=0.003$ ) in New York, and FUSE was longer than EndoRings ( $p=0.004$ ) and standard was longer than Endocuff ( $p=0.050$ ) in Milan.

The mean Boston Bowel Preparation Score overall was 8.12 (1.33), with no significant difference between the study arms, but was higher at Indianapolis ( $8.75 \pm 0.84$ ) and New York ( $8.47 \pm 1.23$ ) than at Milan ( $6.39 \pm 0.76$ ).

There were no colorectal perforations in any of the study patients.

## Discussion

In this prospective randomized controlled trial we compared adenoma detection with a control arm of HD forward-viewing colonoscopy with HD forward-viewing colonoscopy with the adjunctive mucosal exposure devices Endocuff and EndoRings, and with the Full Spectrum Endoscopy (FUSE) colonoscopy system. Although a number of studies have compared individual mucosal exposure devices with standard colonoscopy, to our knowledge this is the first study to compare mucosal exposure devices with each other.

A principal finding of our study was that the FUSE colonoscope system was inferior to high-definition forward-viewing Olympus colonoscopes with or without adjunctive devices. Thus, adenomas per colonoscopy (APC) and the adenoma detection rate (ADR) were higher with Olympus colonoscopes compared with the FUSE system. This result is different than that obtained in the initial tandem colonoscopy study comparing the FUSE system with standard definition colonoscopes<sup>14</sup>, which found that FUSE was superior for detection. Further the result is different from a prospective randomized trial comparing an early generation of FUSE colonoscopes to standard-definition forward-viewing colonoscopes in a FIT positive population in Italy<sup>19</sup>. In that study, there was no difference in detection between the very wide angle FUSE system and the forward-viewing standard-definition colonoscopes. However, there was a non-

significant trend in that study toward better detection of large adenomas by standard endoscopy. In our study, we used high-definition Olympus colonoscopes, and also used state-of-the-art FUSE instruments as they became available during the study interval. Although the FUSE colonoscopes were also considered HD, our subjective impression is that the resolution of the Olympus instruments was superior to FUSE. Our results indicate that in the hands of high-level detectors, high-image resolution is more important to detection than angle of view. Thus, skilled examiners appear to be able to compensate for a more limited angle of view by their manipulation and deflection of the instrument tip to expose mucosal surfaces on the proximal sides of the haustral folds and flexures. Because we found that the FUSE colonoscope was also inferior with regard to the time for cecal insertion, (possibly because the FUSE insertion tubes are “floppier” than Olympus instruments) we conclude that in the hands of careful examiners, high-definition forward-viewing colonoscopes have superior performance to the FUSE colonoscopes. It is possible that a wide angle instrument with image resolution comparable with Olympus high-definition colonoscopes might provide superior detection. However, to our knowledge, no such device exists at the present time, and the FUSE colonoscope is being withdrawn from the commercial market after purchase of EndoChoice by Boston Scientific. Thus, whether a super wide-angle colonoscope can outperform a 170° angle of view high-definition instrument is uncertain and must await development of new technology and further investigation.

Our data indicate that with regard to adjunctive devices that fit over the tip of an HD forward-viewing colonoscope, Endocuff is a dominant strategy over EndoRings and no device. First, there was a significant increase of APC with Endocuff compared to control colonoscopy, and

ADR was higher with Endocuff compared with EndoRings and control colonoscopy. A marked difference in detection with Endocuff at one center, which contributed the smallest group of patients to the overall study, had an important effect on this conclusion, though a numerical increase with a trend toward statistical significance was also seen at the largest participating site. There was no disadvantage with Endocuff with regard to insertion. Thus, overall Endocuff produced improved detection with no detriment to insertion except for an occasional patient with an angulated sigmoid colon in which passage of the colonoscope required removal of the cuff. Further, the finding that Endocuff resulted in gains in detection even in high-level detectors, who would be expected to have superior technique with standard instruments, suggests that Endocuff could potentially produce detection gains for examiners with any baseline level of detection. Thus, Endocuff may overcome mucosal exposure problems that cannot be overcome with an HD forward-viewing colonoscope alone.

In this study, Endocuff allowed an ADR that was at least 7 percentage points higher (95% CI, 3%-16%) than the other 3 arms of the study. A recent study found that each 1% gain in ADR resulted in a 3% drop in the risk of interval cancer and a 5% drop in the risk of fatal interval cancer<sup>3</sup>. Whether such impacts on interval cancer will occur in very high-level detectors is uncertain, but our results indicate that potentially important gains in ADR are achievable with Endocuff even by detectors with very high ADRs using standard instruments. Endocuff was associated with gains in APC of 17% to 40% compared to the other 3 arms. This difference in overall adenoma detection could also result in important protective effects against interval cancer, although the relationship of APC to interval cancer protection has not yet been described. Although we did not formally address the cost-effectiveness of Endocuff, the cost of

Endocuff is low in the United States compared with the cost of colonoscopy, and would be unlikely to adversely affect the cost-effectiveness of improving the quality of adenoma detection<sup>21,22</sup>.

The reasons why EndoRings did not match Endocuff with regard to detection are not clear. From a mucosal exposure perspective, the ability of EndoRings to deflect folds seems comparable to Endocuff. In the left side of the colon, EndoRings seems to have even more of a tendency than Endocuff to straighten the lumen and flatten the haustral folds. However, the mucosal gripping properties of EndoRings seem to cause it to jump back 2 or 3 folds at times during withdrawal through the sigmoid, and it can be difficult to reinsert the instrument to the point where slippage began. In any case, our data suggest that EndoRings creates greater problems for colonoscopy insertion than Endocuff, which certainly relates to its larger diameter and bulkier profile. Taken together, our data suggest that Endocuff is a more effective and easier to use device than EndoRings.

Strengths of our study include large size, the use of multiple centers, and the testing of multiple devices. This design allowed a comparison of available devices in a fashion not previously available to practicing colonoscopists. Further, we used the best available versions of each technology throughout the study. We did not see evidence that successive generations of FUSE or EndoRings were associated with increasing detection, suggesting that our results apply to the latest generations of these devices. Next, we actively forced the inspection times in the 4 study arms to be equal, because withdrawal time is well known to influence detection (23), and failure to control inspection time can disrupt the interpretation of a detection trial<sup>23</sup>.

Limitations of our study were primarily that the recruitment was uneven across the sites, and there were some differences between sites with regard to detection. These differences suggest some operator dependence applies to these devices, such as the very large increase in APC with Endocuff relative to other devices in New York. However many of the trends seen in the overall study were consistent across the individual sites, including the detection of adenomas and serrated lesions, and insertion times. Certainly direct comparisons between mucosal exposure devices by other investigators could be informative. However, we acknowledge that the operator dependence demonstrated in the study indicates that some caution is appropriate in concluding generalizability. Finally, endoscopists were not blinded to which device was in use. This is a consistent problem with colonoscopy detection studies, and these studies depend on the investigating endoscopists approaching the use of each device without bias.

The version of Endocuff that we used is no longer commercially available and has been replaced by Endocuff Vision (Arc Medical Design, Leeds, UK). Endocuff Vision has fingers that are 3 mm longer than those on Endocuff, and there is only one ring of fingers. There are no direct comparative studies of Endocuff Vision and Endocuff. Our anecdotal impression of the fold flattening achieved with Endocuff Vision is that it is as or more effective than Endocuff, with no reduction of insertability. We upgraded the EndoRings and FUSE colonoscopes as upgrades became available during the study. Although the use of upgraded devices makes study interpretation more challenging, we considered that failure to upgrade and using only older devices would also subject the study to criticism. Again, we saw no significant improvement in

ADRs over the course of the study within the EndoRings or FUSE arms, suggesting that our conclusions regarding detection remain valid with the latest generations of these devices.

To the extent that our results endorse the routine use of Endocuff in clinical practice, practitioners might be interested in our impressions of how the device affects actual colonoscopy performance. Our collective impression is that the use of Endocuff in routine colonoscopic examination is easy for experienced endoscopists to learn, and does not adversely affect the performance of routine polypectomies. We suspect it may have the potential to make the process of examining the proximal sides of folds faster, as has been suggested in retrospective uncontrolled evaluations<sup>24</sup>, but which has not been tested as a primary endpoint of randomized trials. We did not routinely or systematically attempt terminal intubation during the study, but our impression was that Endocuff does reduce the ease of and success rate of terminal ileal intubation, consistent with the results of other studies<sup>25</sup>. Finally, attention to difficult sigmoid colons is needed in considering use of Endocuff. In the current study, about 1.5% of subjects had sigmoid colons that did not allow passage of Endocuff, and at Indianapolis about 2% of screened subjects were excluded before randomization because of known diverticular disease that might have made sigmoid passage with Endocuff or EndoRings difficult or impossible. We note that the detection gains found in this study with Endocuff were largely in diminutive lesions (Supplementary Table 1), and the clinical significance of detection gains in diminutive lesions remains uncertain. Improved detection of diminutive lesions may be generally associated with improved detections of large lesions, but that suggestion is not proven true by these data. Further, we did not perform a formal cost analysis of Endocuff use, and have not evaluated the cost-effectiveness of using Endocuff routinely in colonoscopy.

In conclusion, in a prospective randomized controlled trial we demonstrated that detection with high-definition forward-viewing colonoscopes is superior to a very wide angle colonoscope system, which in all its iterations had what seemed to be recognizably inferior image resolution. Thus, in the hands of high-level detectors, image resolution trumps angle of view for adenoma detection during colonoscopy. Next, we showed that use of an adjunct (Endocuff) on the end of a HD forward-viewing colonoscope produced gains in adenoma detection even in the hands of examiners who are very skilled with standard instruments lacking adjunctive devices. Further, Endocuff produced no reduction of insertion capability that was clinically important. Finally, our results indicate that the design of Endocuff is superior to the design of EndoRings as a mucosal exposure device for colonoscopy.

#### References

1. Rex DK. Colonoscopy: the current king of the hill in the USA. *Digestive diseases and sciences* 2015;60:639-46.
2. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. *The New England journal of medicine* 2010;362:1795-803.
3. Corley D, Jensen CD, Marks AR, Zhao W, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. *The New England journal of medicine* 2014;370:1298-306.
4. Rex DK. Colonoscopic withdrawal technique is associated with adenoma miss rates. *Gastrointestinal endoscopy* 2000;51:33-6.
5. Subramanian V, Mannath J, Hawkey CJ, Ragnunath K. High definition colonoscopy vs. standard video endoscopy for the detection of colonic polyps: a meta-analysis. *Endoscopy* 2011;43:499-505.
6. Barclay RL, Vicari JJ, Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2008;6:1091-8.
7. Coe SG, Crook JE, Diehl NN, Wallace MB. An endoscopic quality improvement program improves detection of colorectal adenomas. *The American journal of gastroenterology* 2013;108:219-26; quiz 27.
8. Pohl J, Schneider A, Vogell H, Mayer G, Kaiser G, Ell C. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. *Gut* 2011;60:485-90.
9. Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. *The American journal of gastroenterology* 2010;105:1301-7.
10. Leung WK, Lo OS, Liu KS, et al. Detection of colorectal adenoma by narrow band imaging (HQ190) vs. high-definition white light colonoscopy: a randomized controlled trial. *The American journal of gastroenterology* 2014;109:855-63.

11. Shimoda R, Sakata Y, Fujise T, et al. The adenoma miss rate of blue-laser imaging vs. white-light imaging during colonoscopy: a randomized tandem trial. *Endoscopy* 2017;49:186-90.
12. Chin M, Karnes W, Jamal MM, et al. Use of the Endocuff during routine colonoscopy examination improves adenoma detection: A meta-analysis. *World journal of gastroenterology* 2016;22:9642-9.
13. Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized, tandem evaluation of EndoRings colonoscopy--results of the CLEVER study. *Endoscopy* 2015;47:1151-8.
14. Gralnek IM, Siersema PD, Halpern Z, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. *Lancet Oncol* 2014;15:353-60.
15. Gonzalez-Fernandez C, Garcia-Rangel D, Aguilar-Olivos NE, et al. Higher adenoma detection rate with the endocuff: a randomized trial. *Endoscopy* 2017.
16. Baek MD, Jackson CS, Lunn J, et al. Endocuff assisted colonoscopy significantly increases sessile serrated adenoma detection in veterans. *Journal of gastrointestinal oncology* 2017;8:636-42.
17. Triantafyllou K, Polymeros D, Apostolopoulos P, et al. Endocuff-assisted colonoscopy is associated with a lower adenoma miss rate: a multicenter randomized tandem study. *Endoscopy* 2017.
18. Bhattacharyya R, Chedgy F, Kandiah K, et al. Endocuff-assisted vs. standard colonoscopy in the fecal occult blood test-based UK Bowel Cancer Screening Programme (E-cap study): a randomized trial. *Endoscopy* 2017.
19. Hassan C, Senore C, Radaelli F, et al. Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. *Gut* 2016.
20. Snover D, Ahnen DJ, Burt RW, et al. Serrated polyps of the colon and rectum and serrated ("hyperplastic") polyposis. In: Bozman FT, Carneiro F, Hruban RH, et al, editors. *WHO classification of tumours. Pathology and genetics. Tumours of the digestive system*. 4th edition. Berlin: Springer-Verlag. 2010.
21. Hassan C, Rex DK, Zullo A, Kaminski MF. Efficacy and cost-effectiveness of screening colonoscopy according to the adenoma detection rate. *United European gastroenterology journal* 2015;3:200-7.
22. Meester RG, Doubeni CA, Lansdorp-Vogelaar I, et al. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. *Jama* 2015;313:2349-58.
23. Leufkens AM, DeMarco DC, Rastogi A, et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. *Gastrointestinal endoscopy* 2011;73:480-9.
24. Tsiamoulos ZP, Misra R, Rameshshanker R, et al. Impact of a new distal attachment on colonoscopy performance in an academic screening center. *Gastrointestinal endoscopy* 2018;87:280-7.
25. Gonzalez-Fernandez C, Garcia-Rangel D, Aguilar-Olivos NE, et al. Higher adenoma detection rate with the endocuff: a randomized trial. *Endoscopy* 2017;49:1061-8.

Table 1. Inclusion and exclusion criteria

**Inclusion criteria:**

- Screening, surveillance or diagnostic colonoscopy
- and  $\geq 50$  years of age

**Exclusion criteria:**

- Any large-bowel resection
- inflammatory bowel disease
- Any polyposis syndrome
- Any family history of polyposis syndromes
- Referral for a previous incomplete colonoscopy
- Referral for removal of a polyp
- Referral for positive fecal blood test
- Anticipated severe sigmoid angulation

Table 2. Demographics and procedure indications

	Study arm			
	Control*	Endocuff**	EndoRings***	FUSE
<b>Number of subjects</b>	n = 295	n = 299	n = 295	n = 299
<b>Age(years)</b>	62.6 (8.3)	63.2 (8.2)	62.3 (7.9)	62.3 (8.7)
<b>Female</b>	139 (47%)	141 (47%)	156 (53%)	146 (49%)
<b>Race</b>				
White	272 (92%)	276 (92%)	276 (94%)	269 (90%)
Black	13 (4%)	15 (5%)	13 (4%)	20 (7%)
Hispanic	5 (2%)	6 (2%)	5 (2%)	4 (1%)
Asian	4 (1%)	2 (1%)	1 (<1%)	5 (2%)
Other	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
<b>Indication</b>				
Screening	127 (43%)	126 (42%)	123 (42%)	128 (43%)
Surveillance	151 (51%)	150 (50%)	152 (52%)	154 (52%)
Diagnostic	16 (5%)	23 (8%)	20 (7%)	16 (5%)

\*Control: high-definition forward-viewing Olympus 190 or H180 colonoscope

\*\*Control instrument with Endocuff

\*\*\*Control instrument with EndoRings

FUSE: Full Spectrum Endoscopy

Table 3. Detection endpoints in the intent- to - treat analysis

	Study arm			
	Control	Endocuff	EndoRings	FUSE
<b>Number of subjects</b>	n = 295	n = 299	n = 295	n = 299
<b>Adenomas per colonoscopy</b>				
All sites <sup>+</sup>	1.53 (2.33)*	1.82 (2.58)	1.55 (2.42)	1.30 (1.96)
Indianapolis	1.89 (2.69)	2.17 (2.88)	1.97 (2.77)	1.59 (2.18)
Milan	0.83 (1.18)	0.80 (1.25)	0.72 (1.17)	0.68 (1.19)
New York <sup>++</sup>	0.92 (1.15)	2.00 (2.34)	0.75 (0.94)	0.80 (1.32)
<b>Adenoma detection rate</b>				
All sites <sup>+++</sup>	166 (56%)**	191 (64%)	167 (57%)	154 (52%)
Indianapolis	117 (61%)	137 (70%)	127 (65%)	115 (58%)
Milan	37 (47%)	35 (47%)	29 (39%)	28 (37%)
New York	12 (48%)	19 (68%)	11 (46%)	11 (44%)
<b>SSP per colonoscopy</b>				
All sites <sup>++++</sup>	0.17 (0.54)*	0.17 (0.54)	0.20 (0.81)	0.18 (0.74)
Indianapolis	0.24 (0.64)	0.23 (0.63)	0.29 (0.98)	0.25 (0.89)
Milan	0.03 (0.16)	0.04 (0.26)	0.01 (0.12)	0.03 (0.16)
New York	0.04 (0.20)	0.07 (0.26)	0.04 (0.20)	0.04 (0.20)
<b>SSP detection rate</b>				
All sites <sup>+++++</sup>	36 (12%)**	33 (11%)	33 (11%)	30 (10%)
Indianapolis	33 (17%)	29 (15%)	31 (16%)	27 (14%)
Milan	2 (3%)	2 (3%)	1 (1%)	2 (3%)
New York	1 (4%)	2 (7%)	1 (4%)	1 (4%)
<b>Polyp detection rate</b>				
All sites <sup>+++++</sup>	226 (77%)**	247 (83%)	231 (78%)	212 (71%)
Indianapolis <sup>@</sup>	162 (84%)	175 (89%)	171 (87%)	155 (78%)
Milan	46 (59%)	50 (68%)	42 (56%)	38 (51%)
New York	18 (72%)	22 (79%)	18 (75%)	19 (76%)

\* Designated polyp type per colonoscopy (SD)

\*\* Number of patients with designated polyp type (%)

+ Control, Endocuff, EndoRings higher than FUSE (all  $p < 0.001$ )

+ Endocuff > control ( $p = 0.014$ )

++ Endocuff > EndoRings ( $p = 0.008$ ), FUSE ( $p = 0.011$ ) and control ( $p = 0.027$ ) in New York; no difference in study arms for APC at Indianapolis ( $p = 0.137$ ) or Milan ( $p = 0.848$ )

+++ Endocuff ( $p < 0.001$ ), EndoRings ( $p = 0.001$ ), control ( $p = 0.006$ ) all higher than FUSE. Endocuff higher than EndoRings ( $p < 0.001$ ) and control ( $p = 0.003$ ). No differences in ADR by site

++++ EndoRings higher than FUSE ( $p < 0.001$ ) and control ( $p < 0.001$ ) FUSE higher than control ( $p < 0.001$ )

+++++ Endocuff ( $p = 0.009$ ), control ( $p < 0.001$ ) higher than FUSE. Control higher than Endocuff ( $p = 0.047$ ) and EndoRings ( $p = 0.004$ )

+++++ Endocuff ( $p < 0.001$ ), EndoRings ( $p = 0.002$ ), control ( $p < 0.001$ ) higher than FUSE. Endocuff higher than EndoRings ( $p = 0.008$ ) and control ( $p < 0.001$ )  
@At Indianapolis Endocuff ( $p = 0.004$ ) and EndoRings ( $p = 0.015$ ) higher than FUSE.

Supplementary Table 1. Numbers of histologically proven conventional adenomas and sessile serrated polyps by size and location (right colon = cecum, ascending, and hepatic flexure) in the 4 study arms

Conventional adenomas

		Study Arm
--	--	-----------

Number of subjects		n = 295	n = 299	n = 295	n = 299
Location	Size	Control	Endocuff	EndoRings	FUSE
All	All	445	543	463	385
	1-5mm	336 (76)	424 (78)	342 (74)	299 (78)
	6-9mm	73 (16)	83 (15)	79 (17)	63 (16)
	>=10mm	36 (8)	36 (7)	42 (9)	23 (6)
Distal to the hepatic flexure	All	240	290	250	191
	1-5mm	176 (73)	225 (76)	180 (72)	154 (81)
	6-9mm	45 (19)	46 (16)	48 (19)	28 (15)
	>=10mm	19 (8)	19 (7)	22 (9)	9 (5)
Right Colon	All	205	253	213	194
	1-5mm	160 (78)	199 (79)	162 (76)	145 (75)
	6-9mm	28 (14)	37 (15)	31 (15)	35 (18)
	>=10mm	17 (7)	17 (7)	20 (9)	14 (7)

## Sessile serrated polyps

Number of subjects	Size	Study Arm			
		n = 295	n = 299	n = 295	n = 299
Location	Size	Control	Endocuff	EndoRings	FUSE
All	All	51	50	57	53
	1-5mm	28 (55)	20 (40)	21 (37)	21 (43)
	6-9mm	14 (27)	13 (26)	16 (28)	13 (32)
	>=10mm	9 (18)	17 (34)	20 (35)	19 (36)
Distal to the hepatic flexure	All	31	18	28	28
	1-5mm	19 (49)	9 (50)	13 (46)	12 (43)
	6-9mm	8 (26)	3 (17)	8 (29)	9 (32)
	>=10mm	4 (13)	6 (33)	7 (25)	7 (25)
Right Colon	All	20	32	29	25
	1-5mm	9 (45)	11 (34)	8 (28)	9 (36)
	6-9mm	6 (30)	10 (31)	8 (28)	4 (16)
	>=10mm	5 (25)	11 (34)	13 (45)	12 (48)

\*number of polyps (% of all polyps in this location that are in this size group)

Table 4. Procedure times

	Study arm			
	Control	Endocuff	EndoRings	FUSE
Cecal insertion time seconds(SD)	n = 295	n = 299	n = 295	n = 299

All sites <sup>†</sup>	422 (319)	354 (216)	403 (263)	468 (311)
Indianapolis	366 (243)	320 (179)	352 (191)	395 (225)
Milan	642 (405)	503 (254)	581 (356)	731 (385)
New York	170 (62)	193 (93)	251 (110)	242 (80)
<b>Cecal insertion time when no fellow involved-seconds (SD)</b>	n = 173	n = 169	n = 172	n = 176
All sites <sup>††</sup>	320 (256)	265 (173)	331 (222)	380 (252)
Indianapolis	283 (185)	239 (127)	277 (127)	340 (169)
Milan	556 (378)	438 (269)	588 (345)	718 (401)
<b>Inspection time seconds(SD)</b>	n = 295	n = 299	n = 295	n = 299
All sites <sup>†††</sup>	444 (103)	419 (95)	417 (147)	421 (112)
Indianapolis	418 (91)	392 (89)	388 (160)	378 (83)
Milan	501 (109)	492 (78)	484 (92)	522 (120)
New York	467 (95)	414 (84)	438 (96)	454 (81)

n = number of insertions in designated group performed with no participation by a fellow

<sup>†</sup>FUSE longer than Endocuff (p = 0.006) and control (p = 0.016), EndoRings longer than Endocuff (p = 0.020) (site difference similar but not shown)

<sup>††</sup>When no fellow involved in insertion FUSE longer than Endocuff (p < 0.001), EndoRings (p = 0.017) and control (p = 0.001) EndoRings longer than Endocuff (p = 0.014)

By site: FUSE longer than Endocuff and control at all sites; EndoRings longer than Endocuff and control in New York, FUSE longer than EndoRings in Milan, control longer than Endocuff in Milan.

<sup>†††</sup>No significant difference overall. By site, control significantly shorter than Endocuff, EndoRings, and FUSE in Indianapolis.

Supplementary Table 2: Detection endpoints in the per protocol analysis

	Study arm			
	Control	Endocuff	Endorings	FUSE
<b>Number of subjects</b>	n = 295	n = 299	n = 295	n = 299
<b>Adenomas per colonoscopy</b>				
All sites <sup>†</sup>	1.53 (2.33)*	1.84 (2.59)	1.57 (2.43)	1.30 (1.96)
Indianapolis	1.89 (2.69)	2.21 (2.88)	1.98 (2.78)	1.59 (2.18)
Milan	0.83 (1.18)	0.80 (1.25)	0.72 (1.18)	0.68 (1.19)

New York <sup>++</sup>	0.92 (1.15)	2.07 (2.35)	0.82 (0.96)	0.83 (1.34)
<b>Adenoma detection rate</b>				
All sites <sup>+++</sup>	166 (56%)**	191 (65%)	165 (57%)	154 (52%)
Indianapolis	117 (61%)	137 (71%)	126 (65%)	115 (58%)
Milan	37 (47%)	35 (47%)	28 (38%)	28 (37%)
New York	12 (48%)	19 (70%)	11 (50%)	11 (46%)
<b>SSP per colonoscopy</b>				
All sites <sup>++++</sup>	0.17 (0.54)*	0.17 (0.54)	0.20 (0.82)	0.18 (0.54)
Indianapolis	0.24 (0.64)	0.23 (0.63)	0.30 (0.98)	0.25 (0.89)
Milan	0.03 (0.16)	0.04 (0.26)	0.01 (0.12)	0.03 (0.16)
New York	0.04 (0.20)	0.07 (0.27)	0.05 (0.21)	0.04 (0.20)
<b>SSP detection rate</b>				
All sites <sup>+++++</sup>	36 (12%)**	33 (11%)	33 (11%)	30 (10%)
Indianapolis	33 (17%)	29 (15%)	31 (16%)	27 (14%)
Milan	2 (3%)	2 (3%)	1 (1%)	2 (3%)
New York	1 (4%)	2 (7%)	1 (5%)	1 (4%)
<b>Polyp detection rate</b>				
All sites <sup>+++++</sup>	22 (77%)*	247 (84%)	229 (79%)	213 (71%)
Indianapolis <sup>@</sup>	163 (85%)	174 (90%)	171 (89%)	156 (78%)
Milan	46 (59%)	50 (68%)	41 (55%)	38 (51%)
New York	19 (76%)	23 (85%)	17 (77%)	19 (79%)

\* Designated polyp type per colonoscopy (SD)

\*\* Number of patients with designated polyp type (%)

+ Standard, Endocuff, Endorings higher than FUSE (all  $p < 0.001$ )

+ Endocuff > Endorings ( $p = 0.048$ ) and standard ( $p = 0.004$ )

++ Endocuff > Endorings ( $p = 0.011$ ), FUSE ( $p = 0.010$ ) and standard ( $p = 0.018$ ) in New York; no difference in study arms for APC at Indianapolis ( $p = 0.16$ ) or Milan ( $p = 0.845$ )

+++ Endocuff ( $p < 0.001$ ), Endorings ( $p = 0.004$ ), standard ( $p = 0.007$ ) all higher than FUSE. Endocuff higher than Endorings ( $p < 0.001$ ) and standard ( $p = 0.004$ ). No differences in ADR by site

++++ Endorings higher than FUSE ( $p < 0.001$ ) and standard ( $p < 0.001$ ) FUSE higher than standard ( $p < 0.001$ )

+++++ Endocuff ( $p = 0.002$ ), Endorings ( $p = 0.041$ ), standard ( $p < 0.001$ ) higher than FUSE. Standard higher than Endorings ( $p = 0.015$ )


+++++ Endocuff ( $p < 0.001$ ), Endorings ( $p = 0.009$ ), standard ( $p < 0.001$ ) higher than FUSE. Endocuff higher than Endorings ( $p = 0.16$ ) and standard ( $p < 0.001$ )


@At Indianapolis Endocuff ( $p = 0.003$ ) and Endorings ( $p = 0.007$ ) higher than FUSE.

## Figure Legends

Figure 1: Flow of patients through the study.

Figure 2: The Endocuff (left) and the revised EndoRings (right) devices used in the study.





ACCEPTED MANUSCRIPT

## Acronyms

FUSE: Full-Spectrum Endoscopy

HD: high definition

APC: adenomas per colonoscopy

ADR: adenoma detection rate

DR: Douglas Rex

AR: Alessandro Repici

SG: Seth Gross

U.S.A: United States of America

MN: Minnosta

APC: adenomas per colonoscopy

SSPC: sessile serrated polyps per colonoscopy

SPDR: sessile serrated detection rate

GEE: generalized estimating equation

BBPS: Boston Bowel Preparation Score

NC: North Carolina

PDR: polyp detection rate

SSP: sessile serrated polyps

FIT: fecal immunochemical test

US: United States

SD: standard deviation